MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413710 | Name: Dicycloplatin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dicycloplatin has antineoplastic activity; a supramolecular complex of 1,1-cyclobutane dicarboxylic acid and cis-diammine(1,1-cyclobutane dicarboxylate)platinum (II).

Chemical Structure

Dicycloplatin
CAS#287402-09-9

Theoretical Analysis

MedKoo Cat#: 413710

Name: Dicycloplatin

CAS#: 287402-09-9

Chemical Formula: C12H20N2O8Pt

Exact Mass: 515.0867

Molecular Weight: 515.38

Elemental Analysis: C, 27.97; H, 3.91; N, 5.44; O, 24.83; Pt, 37.85

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Dicycloplatin; UNII-0KC57I4UNB
IUPAC/Chemical Name
1,1-Cyclobutanedicarboxylic acid, compd. with (sp-4-2)-diammine(1,1-cyclobutanedi(carboxylato-kappaO)(2-))platinum (1:1)
InChi Key
IIJQICKYWPGJDT-UHFFFAOYSA-L
InChi Code
InChI=1S/2C6H8O4.2H3N.Pt/c2*7-4(8)6(5(9)10)2-1-3-6;;;/h2*1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;;+2/p-2
SMILES Code
OC(C1(C(O)=O)CCC1)=O.[O-]C(C2(C([O-])=O)CCC2)=O.N.N.[Pt+2]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 515.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Yu JJ, Hogan T, Morley C, Crigger C, Jiao S, Williams DJ, Salkini MW, Yang X, Liang X, Yan B, Cecil C, Winn AC, Zheng J, Guo YI, Jiang BH, Washington IM. Adverse Effects Profile of Dicycloplatin (DCP) Offers Chemotherapeutic Advantage Over Cisplatin and Carboplatin. Anticancer Res. 2019 Aug;39(8):4455-4462. doi: 10.21873/anticanres.13618. PMID: 31366544. 2: Yu JJ, Yang X, Song Q, Mueller MD, Remick SC. Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res. 2014 Jan;34(1):455-63. PMID: 24403501. 3: Xu LJ, Gao RL, Wu C, Ye J, Song L, Qian X. Dicycloplatin differentially inhibits proliferation of human aortic smooth muscle and endothelial cells: potential for use in drug-eluting stents. Chin Med J (Engl). 2012 Dec;125(24):4386-92. PMID: 23253707. 4: Yang X, Zheng J, Song Q, Xie F, Tang J, Chen J, Wu J, Li C, Cui W, Tang Y, Xie J, Zheng J. Determination methods for the anticancer drug dicycloplatin, a supramolecule assembled through hydrogen bonding. Analyst. 2015 Apr 21;140(8):2704-12. doi: 10.1039/c4an02274b. Epub 2015 Feb 16. PMID: 25686082. 5: Li GQ, Chen XG, Wu XP, Xie JD, Liang YJ, Zhao XQ, Chen WQ, Fu LW. Effect of dicycloplatin, a novel platinum chemotherapeutical drug, on inhibiting cell growth and inducing cell apoptosis. PLoS One. 2012;7(11):e48994. doi: 10.1371/journal.pone.0048994. Epub 2012 Nov 12. PMID: 23152837; PMCID: PMC3495782. 6: Wei W, Liu Z, Chen X, Bi F. Chemosensitivity of resistant colon cancer cell lines to lobaplatin, heptaplatin, and dicycloplatin. Int J Clin Pharmacol Ther. 2014 Aug;52(8):702-7. doi: 10.5414/CP202023. PMID: 24986092. 7: Liu KJ, Guan ZZ, Liang Y, Yang XQ, Peng J, Huang H, Shao QX, Wang MZ, Zhu YZ, Wu CP, Wang SB, Xiong JP, Bai YX, Yu SY, Zhang Y, Hu XH, Feng JF, Wu SX, Jiao SC, Zhou CC, Wang J, Wu HY. A double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancers. Arch Med Sci. 2014 Aug 29;10(4):717-24. doi: 10.5114/aoms.2014.44862. PMID: 25276156; PMCID: PMC4175772. 8: Li S, Huang H, Liao H, Zhan J, Guo Y, Zou BY, Jiang WQ, Guan ZZ, Yang XQ. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results. Int J Clin Pharmacol Ther. 2013 Feb;51(2):96-105. doi: 10.5414/CP201761. PMID: 23127487. 9: Zhao D, Zhang Y, Xu C, Dong C, Lin H, Zhang L, Li C, Ren S, Wang X, Yang S, Han D, Chen X. Pharmacokinetics, tissue distribution, and plasma protein binding study of platinum originating from dicycloplatin, a novel antitumor supramolecule, in rats and dogs by ICP-MS. Biol Trace Elem Res. 2012 Aug;148(2):203-8. doi: 10.1007/s12011-012-9364-2. Epub 2012 Feb 28. PMID: 22367705. 10: Apps MG, Choi EH, Wheate NJ. The state-of-play and future of platinum drugs. Endocr Relat Cancer. 2015 Aug;22(4):R219-33. doi: 10.1530/ERC-15-0237. Epub 2015 Jun 25. PMID: 26113607.